Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04882098 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
A Phase 3 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 1,054
- Enrollment target
- 20
- Study locations
NCT04882098 is a Phase 3 study of Arthritis, Psoriatic that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 1,054 participants, above the 511-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (106% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT04882098, a Phase 3 study of Arthritis, Psoriatic, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,054 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guselkumab
Study Locations (20)
Arizona
- Arizona Arthritis and Rheumatology Research PLLC - Flagstaff
- Arizona Arthritis & Rheumatology Associates PC - Glendale
- Arizona Arthritis & Rheumatology Research, PLLC - Tucson
California
- Advanced Medical Research - La Palma
- Rheumatology Center of San Diego - San Diego
- Medvin Clinical Research, Inc. - Whittier
Florida
- Heuer M.D. Research - Orlando
- The Arthritis Center, Inc. - Palm Harbor
- Forcare Clinical Research Inc - Tampa
Alabama
- Rheumatology Associates - Birmingham
Maryland
- Klein And Associates M D P A - Hagerstown
Michigan
- Advanced Rheumatology - Okemos
Missouri
- Arthritis Consultants - St Louis
Montana
- Glacier View Research Institute - Kalispell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,054 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2027-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04882098
The ClinicalTrials.gov registry entry for NCT04882098 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,054 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 511-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (106% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04882098 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04882098 about?
NCT04882098 is a clinical study titled "A Study of Guselkumab in Participants With Active Psoriatic Arthritis". The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
What is the current status of trial NCT04882098?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,054 participants. The study started on 2021-06-17. Estimated completion is 2027-10-05.
What conditions does trial NCT04882098 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT04882098?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT04882098?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04882098 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.